Jones, Helen E - Cardiff University - School of Biosciences

个人简介

After gaining a degree in Biomedical Sciences, I undertook my Ph.D. in Cell Biology in the Department of Zoology in Cardiff University, where I investigated the role of programmed cell death occurring during the metamorphosis of Drosophila melanogaster. Several postdoctoral positions later, which encompassed the areas of toxicology, prostate cancer and cell imaging, I returned to the field of cancer research, gaining an AstraZeneca funded position in the Tenovus Centre for Cancer Research in the Welsh School of Pharmacy in Cardiff University. This position lasted 7 years, where I elucidated the mechanisms of de novo and acquired resistance to novel 'intelligent' anticancer therapies which target growth factor receptors and their signalling transduction cascades. I subsequently joined the School of Biosciences as a Professional Tutor and I am extending my areas of interest into pedagogic topics. To this end, I have recently become a Fellow of the Higher Education Academy.

研究领域

My general interest is in the area of cell biology, specifically in the topics of cell signalling, cancer biology and programmed cell death. My speciality is the role of cell signalling in disease processes, with specific expertise regarding aberrant cell signalling mechanisms that lead to the development and progression of cancer. Such interests also encompass how cancer-related deregulated signalling can be therapeutically targeted using novel anti-cancer strategies.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Law, J.et al. 2008. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Research 68(24), pp. 10238-10246. (10.1158/0008-5472.CAN-08-2755) Knowlden, J.et al. 2008. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 111(1), pp. 79-91. (10.1007/s10549-007-9763-9) Hutcheson, I.et al. 2006. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer 13(S1), pp. S89-S97. (10.1677/erc.1.01279) Jones, H.et al. 2006. Growth factor receptor interplay and resistance in cancer. Endocrine-Related Cancer 13(S1), pp. S45-S51. (10.1677/erc.1.01275) Jones, H.et al. 2006. Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. British Journal of Cancer 95(2), pp. 172-180. (10.1038/sj.bjc.6603237) Jones, H.et al. 2006. Growth factor pathway switching: implications for the use of gefitinib and trastuzumab. Breast Cancer Online 9(7), article number: e27. (10.1017/S1470903106005451) Jones, H.et al. 2006. Maintenance of EGFR phosphorylation by the IGF-1R in the presence of gefitinib in lung cancer cells: Co-targeting the EGFR and IGF-1R maximises anti-tumour effects [Abstract]. Annals of Oncology 17(S3), pp. iii39. (10.1093/annonc/mdl919) Jones, H.et al. 2005. Development of strategies for the use of anti-growth factor treatments. Endocrine-Related Cancer 12(S1), pp. S173-S182. (10.1677/erc.1.01004)